Cargando…

Limiting antipsychotic drugs in dementia

Most patients with dementia have behavioural and psychological symptoms. The first-line treatments for these symptoms are not drugs, but behavioural and psychological interventions Antipsychotic drugs are widely prescribed for people living with dementia. This is despite a high adverse effect burden...

Descripción completa

Detalles Bibliográficos
Autores principales: Macfarlane, Stephen, Cunningham, Colm
Formato: Online Artículo Texto
Lenguaje:English
Publicado: NPS MedicineWise 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7900276/
https://www.ncbi.nlm.nih.gov/pubmed/33664543
http://dx.doi.org/10.18773/austprescr.2020.078
_version_ 1783654190377074688
author Macfarlane, Stephen
Cunningham, Colm
author_facet Macfarlane, Stephen
Cunningham, Colm
author_sort Macfarlane, Stephen
collection PubMed
description Most patients with dementia have behavioural and psychological symptoms. The first-line treatments for these symptoms are not drugs, but behavioural and psychological interventions Antipsychotic drugs are widely prescribed for people living with dementia. This is despite a high adverse effect burden and limited evidence of efficacy Most behavioural and psychological symptoms will subside spontaneously within six months. Trials of deprescribing are therefore recommended Behaviours should be seen as symptoms that have an underlying cause. Treatment should target these causes, rather than the resultant behaviours
format Online
Article
Text
id pubmed-7900276
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher NPS MedicineWise
record_format MEDLINE/PubMed
spelling pubmed-79002762021-03-03 Limiting antipsychotic drugs in dementia Macfarlane, Stephen Cunningham, Colm Aust Prescr Article Most patients with dementia have behavioural and psychological symptoms. The first-line treatments for these symptoms are not drugs, but behavioural and psychological interventions Antipsychotic drugs are widely prescribed for people living with dementia. This is despite a high adverse effect burden and limited evidence of efficacy Most behavioural and psychological symptoms will subside spontaneously within six months. Trials of deprescribing are therefore recommended Behaviours should be seen as symptoms that have an underlying cause. Treatment should target these causes, rather than the resultant behaviours NPS MedicineWise 2021-02-01 2021-02 /pmc/articles/PMC7900276/ /pubmed/33664543 http://dx.doi.org/10.18773/austprescr.2020.078 Text en (c) NPS MedicineWise http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial No Derivatives (CC BY-NC-ND) 4.0 License.
spellingShingle Article
Macfarlane, Stephen
Cunningham, Colm
Limiting antipsychotic drugs in dementia
title Limiting antipsychotic drugs in dementia
title_full Limiting antipsychotic drugs in dementia
title_fullStr Limiting antipsychotic drugs in dementia
title_full_unstemmed Limiting antipsychotic drugs in dementia
title_short Limiting antipsychotic drugs in dementia
title_sort limiting antipsychotic drugs in dementia
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7900276/
https://www.ncbi.nlm.nih.gov/pubmed/33664543
http://dx.doi.org/10.18773/austprescr.2020.078
work_keys_str_mv AT macfarlanestephen limitingantipsychoticdrugsindementia
AT cunninghamcolm limitingantipsychoticdrugsindementia